Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma

Journal of Clinical Oncology

Volumn 25, Issue 6, 2007, Pages 698-707

  Izzo, Julie G ^a   Wu, Tsung Teh ^a   Wu, Xifeng ^a   Ensor, Joe ^a   Luthra, Rajyalakshmi ^a   Pan, Jennifer ^a   Correa, Arlene ^a   Swisher, Stephen G ^a   Chao, Clifford K S ^a   Hittelman, Walter N ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; BIOLOGICAL MARKER; CD1B ANTIGEN; CYCLIN D1; GUANINE; T6 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ALLELE; ARTICLE; BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CANCER SURVIVAL; CHROMOSOME 9; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; DRUG TARGETING; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOMIC INSTABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR EVOLUTION; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; ADENOCARCINOMA; COHORT ANALYSIS; DISEASE COURSE; ESOPHAGOSCOPY; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; PATHOLOGY; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL;

ADENINE; ADENOCARCINOMA; ADULT; AGED; BIOPSY, NEEDLE; COHORT STUDIES; CYCLIN D1; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOSCOPY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; GUANINE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33947611435     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.0283     Document Type: Article

References (49)

1. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005
2. Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature 396:643-649, 1998
3. Maley CC, Reid BJ: Natural selection in neoplastic progression of Barrett's esophagus. Semin Cancer Biol 15:474-483, 2005
4. Hanahan D, Weinber RA: The hallmarks of cancer. Cell 100:57-70, 2000
5. Maley CC, Galipeau PC, Li X, et al: The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res 64:7629-7633, 2004
6. Paulson TG, Reid BJ: Focus on Barrett's esophagus and esophageal adenocarcinoma. Cancer Cell 6:11-16, 2004
7. Sato F, Meltzer SJ: CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer 106:483-493, 2005
8. Schulmann K, Sterian A, Berki A, et al: Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 24:4138-4148, 2005
9. Bani-Hani K, Martin IG, Hardie LJ, et al: Prospective study of cyclin D1 overexpression in Barrett's esophagus: Association with increased risk of adenocarcinoma. J Natl Cancer Inst 92:1316-1321, 2000
10. Arber N, Lightdale C, Rotterdam H, et al: Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 5:457-459, 1996
11. Arber N, Gammon MD, Hibshoosh H, et al: Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach. Hum Pathol 30:1087-1092, 1999
12. Trudgill NJ, Suvarna SK, Royds JA, et al: Cell cycle regulation in patients with intestinal metaplasia at the gastro-oesophageal junction. Mol Pathol 56:313-317, 2003
13. Sherr CJ: D-type cyclins. Trends Biochem Sci 20:187-190, 1995
14. Sherr CJ, Roberts JM: CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512, 1999
15. Zhang P: The cell cycle and development: Redundant roles of cell cycle regulators. Curr Opin Cell Biol 11:655-662, 1999
16. Zhou P, Jiang W, Weghorst CM, et al: Overexpression of cyclin D1 enhances gene amplification. Cancer Res 56:36-39, 1996
17. Nelsen CJ, Kuriyama R, Hirsch B, et al: Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy. J Biol Chem 280:768-776, 2005
18. Wang TC, Cardiff RD, Zukerberg L, et al: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669-671, 1994
19. Donnellan R, Chetty R: Cyclin D1 and human neoplasia. Mol Pathol 51:1-7, 1998
20. Hassan A, Yerian LM, Kuan SF, et al: Immunohistochemical evaluation of adenomatous polyposis coli, beta-catenin, c-Myc, cyclin D1, p53, and retinoblastoma protein expression in syndromic and sporadic fundic gland polyps. Hum Pathol 35:328-334, 2004
21. Miller CT, Moy JR, Lin L, et al: Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin Cancer Res 9:4819-4825, 2003
22. Betticher DC, Thatcher N, Altermatt HJ, et al: Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11:1005-1011, 1995
23. Kong S, Wei Q, Amos CI, et al: Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. J Natl Cancer Inst 93:1106-1108, 2001
24. Kong S, Amos CI, Luthra R, et al: Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 60:249-252, 2000
25. Zheng Y, Shen H, Sturgis EM, et al: Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: A case-control study. Carcinogenesis 22:1195-1199, 2001
26. Izzo JG, Papadimitrakopoulou VA, Liu DD, et al: Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 95:198-205, 2003
27. Knudsen KE, Diehl JA, Haiman CA, et al: Cyclin D1: Polymorphism, aberrant splicing and cancer risk. Oncogene 25:1620-1628, 2006
28. Diehl JA, Zindy F, Sherr CJ: Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 11:957-972, 1997
29. Diehl JA, Cheng M, Roussel MF, et al: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12:3499-3511, 1998
30. Alt JR, Cleveland JL, Hannink M, et al: Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 14:3102-3114, 2000
31. Hosokawa Y, Arnold A: Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: Analysis of allele-specific expression. Genes Chromosomes Cancer 22:66-71, 1998
32. Lu F, Gladden AB, Diehl JA: An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 63:7056-7061, 2003
33. Casson AG, Zheng Z, Evans SC, et al: Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma. Cancer 104:730-739, 2005
34. Geddert H, Kiel S, Zotz RB, et al: Polymorphism of p16 (INK4A) and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol 131:803-808, 2005
35. Wang R, Zhang JH, Li Y, et al: The association of cyclin D1 (A870G) polymorphism with susceptibility to esophageal and cardiac cancer in north Chinese population. Zhonghua Yi Xue Za Zhi 83:1089-1092, 2003
36. Zhang J, Li Y, Wang R, et al.: Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardiac carcinoma in a northern Chinese population. Int J Cancer 105:281-284, 2003
37. Union Internationale Contre le Cancer: TNM Classification of Malignant Tumors (ed 6). New York, NY Wiley-Liss, 2002
38. Haggitt RC: Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 25:982-993, 1994
39. Papadimitrakopoulou V, Izzo J, Lippman SM, et al: Frequent inactivation of p16INK4a in oral premalignant lesions. Oncogene 14:1799-1803, 1997
40. Ratschiller D, Heighway J, Gugger M, et al: Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol 21:2085-2093, 2003
41. Roh HJ, Shin DM, Lee JS, et al: Visualization of the timing of gene amplification during multistep head and neck tumorigenesis. Cancer Res 60:6496-6502, 2000
42. Kim J, Shin DM, El Naggar A, et al: Chromosome polysomy and histological characteristics in oral premalignant lesions. Cancer Epidemiol Biomarkers Prev 10:319-325, 2001
43. Dhingra K, Sneige N, Pandita TK, et al: Quantitative analysis of chromosome in situ hybridization signal in paraffin-embedded tissue sections. Cytometry 16:100-112, 1994
44. Papadimitrakopoulou VA, Liu DD, Mao L, et al: Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions. Cancer Epidemiol Biomarkers Prev 11:1605-1610, 2002
45. Izzo JG, Malhotra U, Wu TT, et al: Impact of cyclin D1 A870G polymorphism in esophageal adenocarcinoma tumorigenesis. Semin Oncol 32:S11-S15, 2005 (suppl)
46. Rajagopalan H, Lengauer C: Aneuploidy and cancer. Nature 423:338-341, 2004
47. Lee JJ, Hong WK, Hittelman WN, et al: Predicting cancer development in oral leukoplakia: Ten years of translational research. Clin Cancer Res 6:1702-1710, 2000
48. Voravud N, Shin DM, Ro JY, et al: Increased polysomies of chromosomes 7 and 17 during head and neck multistage tumorigenesis. Cancer Res 53:2874-2883, 1993
49. Lee JS, Kim SY, Hong WK, et al.: Detection of chromosomal polysomy in oral leukoplakia, a premalignant lesion. J Natl Cancer Inst 85:1951-1954, 1993